Evidence map›Paper›PMID 34766166›Full record

ArticleArchives of pharmacology and therapeutics2021

Kameswari S Konduri, Ram Pattisapu, Jogi Pattisapu, Girija G Konduri, John Zwetchkenbaum, Bidhan Roy, Monalisa Barman, Adria Frazier, Brett L Hurst, Nejat Düzgüneş

Open access · hybridAbstract read
In one paragraph

Article in Archives of pharmacology and therapeutics, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.3field-weighted citation impact, top 39% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 2 citations in OpenAlex.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 5 institutions in 1 country.

Kameswari S KonduriVGSK Technologies, Inc, Madison, WI USA.
Ram PattisapuVGSK Technologies, Inc, Madison, WI USA.
Jogi PattisapuUniversity of Central Florida, Orlando, FL USA.
Girija G KonduriMedical College of Wisconsin, Milwaukee, WI USA.
John ZwetchkenbaumVGSK Technologies, Inc, Madison, WI USA.
Bidhan RoyVGSK Technologies, Inc, Madison, WI USA.
Monalisa BarmanVGSK Technologies, Inc, Madison, WI USA.
Adria FrazierUniversity of the Pacific School of Dentistry, San Francisco, CA USA.
Brett L HurstUtah State University, Logan, UT USA.
Nejat DüzgüneşUniversity of the Pacific School of Dentistry, San Francisco, CA USA.
MP Technologies (United States) · USUniversity of the Pacific · USMedical College of Wisconsin · USUniversity of Central Florida · USUtah State University · US

Funding

T CELL MEMORY TO VIRUSESR01AI030048 · NIAID · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI AHMED, RAFI · 1990 to 2022
$5.2M
T CELL MEMORY TO VIRUSESR37AI030048 · NIAID · EMORY UNIVERSITY · PI AHMED, RAFI · 2001 to 2010
$3.9M
NIAID NIH HHS N01 AI030048
6 · The paper itself

Abstract

backgroundInhaled budesonide benefits patients with COVID-19.

objectiveTo determine the efficacy of

methodsSARS-CoV-2-infected Vero 76 cells were treated with

results

conclusions

Identifiers

PMID34766166
PMCPMC8580381
OpenAlexW3210606402

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.